Trial Profile
Randomized Trial Assessing the Significance of Bevacizumab in Recurrent Grade II and Grade III Gliomas - The TAVAREC Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Temozolomide (Primary)
- Indications Astrocytoma; Glioma; Oligodendroglioma
- Focus Therapeutic Use
- Acronyms TAVAREC
- 19 Jun 2023 Results assessing the impact of the addition of BEV to TMZ on Health-related quality of life published in the European Journal of Cancer
- 16 Mar 2022 Results assessing prognostic significance of DNA methylation profiles at MRI enhancing tumor recurrence published in the Clinical Cancer Research
- 13 Aug 2018 Results published in the Lancet Oncology